January 2, 2007 -- The biggest winners in the 2006 biotech market were not Amgen or Genentech. The two giants ended the year with losses of 12% and 14% respectively. And even our favorites, Celgene and Gilead, up 85% and 20% respectively, could not match top instrument and reagent maker Illumina’s 150% gain. But Illumina was not the only instrument maker making hay. We look at how individual reagent and tool companies did last year and at the implications of that performance for biotech research and development...
